Irreversible Electroporation Combined With Dendritic Cell-based Vaccines for the Treatment of Osteosarcoma
Anticancer Research · 2023
DOI: 10.21873/anticanres.16514 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Anticancer Research, 2023. Verfasst von Chong Sun und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Spinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, P.R. China. Hauptthemen laut MEDLINE: Cancer Vaccines, Osteosarcoma, Bone Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Osteosarcoma is the most common primary bone malignancy, and surgical resection combined with neoadjuvant chemotherapy is the gold-standard treatment for affected patients. Although the overall survival rates for patients with osteosarcoma currently range from 60% to 70%, outcomes remain disappointing for patients with recurrent, metastatic, or unresectable disease. Irreversible electroporation (IRE) is a novel ablation technique with the potential to elicit an immune response in solid tumors. Dendritic cell (DC)-based tumor vaccines have shown promising therapeutic efficacy in preclinical studies focused on osteosarcoma; however, only limited therapeutic efficacy has been observed in clinical trials. Thus, there is considerable potential therapeutic value in developing combination osteosarcoma treatments that involve IRE and DC-based tumor vaccines. In this review, we discuss recent advances in preclinical and clinical DC-based immunotherapies, as well as potential combinations of DC-based vaccines and IRE, that may improve therapeutic outcomes for patients with osteosarcoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Spinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, P.R. China.
- Department of Radiological Sciences, University of California Irvine, Irvine, CA, U.S.A.; zhuoliz1@hs.uci.edu.
- Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA, U.S.A.
- Department of Biomedical Engineering, University of California Irvine, Irvine, CA, U.S.A.
- Department of Pathology and Laboratory Medicine, University of California Irvine, Irvine, CA, U.S.A.
- Department of Spinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, P.R. China; guojw_qdfy@163.com.
Förderung
- NCI NIH HHS
Zitieren
APA
Sun, C., Ma, X., Zhou, C., Zhang, Z., & Guo, J. (2023). Irreversible Electroporation Combined With Dendritic Cell-based Vaccines for the Treatment of Osteosarcoma. Anticancer Research. https://doi.org/10.21873/anticanres.16514
Vancouver
Sun C, Ma X, Zhou C, Zhang Z, Guo J. Irreversible Electroporation Combined With Dendritic Cell-based Vaccines for the Treatment of Osteosarcoma. Anticancer Research. 2023. doi:10.21873/anticanres.16514
BibTeX
@article{Sun2023,
author = {Sun, Chong and Ma, Xuexiao and Zhou, Chuanli and Zhang, Zhuoli and Guo, Jianwei},
title = {Irreversible Electroporation Combined With Dendritic Cell-based Vaccines for the Treatment of Osteosarcoma},
journal = {Anticancer Research},
year = {2023},
doi = {10.21873/anticanres.16514}
}
EUVIMED